Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,407.50GBp
11:52am EDT
Change (% chg)

23.50 (+1.70%)
Prev Close
1,384.00
Open
1,384.50
Day's High
1,434.00
Day's Low
1,378.00
Volume
208,955
Avg. Vol
615,765
52-wk High
1,636.00
52-wk Low
814.20

Chart for

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company's segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products... (more)

Overall

Beta: 1.35
Market Cap(Mil.): £3,375.65
Shares Outstanding(Mil.): 241.42
Dividend: 17.01
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): -- 29.73 33.88
EPS (TTM): -2.82 -- --
ROI: -29.57 13.68 13.21
ROE: -45.63 15.46 15.18

GSK wins new reprieve as Hikma's generic Advair delayed again

GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

Mar 12 2018

UPDATE 1-GSK wins new reprieve as Hikma's generic Advair delayed again

March 12 GlaxoSmithKline has won a further reprieve for its blockbuster Advair lung drug after U.S. regulators insisted Hikma Pharmaceuticals conduct a further clinical study evaluating its generic version of the drug.

Mar 12 2018

BRIEF-Hikma Gets U.S. FDA Response On ANDA For Generic Version Of GSK's Advair Diskus

* HAS RECEIVED A RESPONSE FROM U.S. FDA IN RELATION TO ITS ANDA FOR ITS GENERIC VERSION OF GLAXOSMITHKLINE'S ADVAIR DISKUS

Mar 12 2018

Hikma plans new clinical study over generic Advair

March 12 Hikma Pharmaceuticals Plc said on Monday it plans a new clinical study on its generic version of GlaxoSmithKline's popular lung drug Advair, as it looks to resolve an ongoing dispute with the Food and Drug Administration over plans to launch the drug in the U.S.

Mar 12 2018

UPDATE 1-Drugmaker Hikma names former Teva exec Olafsson as CEO; shares up

Feb 20 Hikma Pharmaceuticals Plc named former Teva Pharmaceutical executive Sigurdur Olafsson as its CEO, as the Jordan-based drugmaker looks to improve its struggling generics business.

Feb 20 2018

BRIEF-Hikma Pharmaceutical Names Sigurdur Olafsson As CEO

* SAYS OLAFSSON WILL ALSO JOIN HIKMA'S BOARD OF DIRECTORS AS AN EXECUTIVE DIRECTOR

Feb 20 2018

Drugmaker Hikma appoints Sigurdur Olafsson as CEO

Feb 20 Drugmaker Hikma Pharmaceuticals Plc said on Tuesday it appointed Sigurdur Olafsson as its chief executive, effective immediately.

Feb 20 2018

Earnings vs. Estimates